Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q3 2021 13F Holders as of 30 Sep 2021
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 16,206,198
- Total 13F value
- $85,726,624
- Share change
- -380,704
- Put/Call ratio
- 15%
- SEC-reported price per share
- $5.29
- Number of holders
- 48
- Value change
- -$2,862,733
- Number of buys
- 14
- Number of sells
- 34
- Shares outstanding
- 94,372,096
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2021
Institutions
48
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2021
Previous quarter: Q2 2021
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ikarian Capital, LLC
Disclosed value leader
Ikarian Capital, LLC
Comparable rows
15/15
Latest evidence
30 Jun 2021
13F
Lead comparable stake: 2.9%
Showing 1-6 of 15 holder rows.
Quick read
Ikarian Capital, LLC leads the comparable SEC ownership view at 2.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ikarian Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Ikarian Capital, LLC
2.9%
Bain Capital Life Sciences Invest...
2.2%
AIGH Capital Management LLC
1.5%
ORBIMED ADVISORS LLC
1.5%
VANGUARD GROUP INC
0.95%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13F
Company
|
2.9%
|
$17,676,000
2,719,290 shares
|
— | 30 Jun 2021 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
2.2%
|
$13,777,000
2,119,540 shares
|
— | 30 Jun 2021 |
| AIGH Capital Management LLC |
13F
Company
|
1.5%
|
$9,353,000
1,438,899 shares
|
— | 30 Jun 2021 |
| ORBIMED ADVISORS LLC |
13F
Company
|
1.5%
|
$8,930,000
1,373,849 shares
|
— | 30 Jun 2021 |
| VANGUARD GROUP INC |
13F
Company
|
0.95%
|
$5,834,000
897,641 shares
|
— | 30 Jun 2021 |
| BVF INC/IL |
13F
Company
|
0.9%
|
$5,511,000
847,879 shares
|
— | 30 Jun 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2021
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
48
Shares
16,206,198
Rows available
48
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2021 vs Q2 2021 Across Filers
Q2 2021 holders
58
Q3 2021 holders
48
Holder diff
-10
| Investor | Q2 2021 Shares | Q3 2021 Shares | Share Diff | Share Chg % | Q2 2021 value | Q3 2021 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend